New ESMO guidelines for the diagnosis, treatment and follow-up of small cell lung cancer
The guidelines of the European Society of Medical Oncology (ESMO) are publications that guide the clinical practice of Oncologists in Europe and worldwide, for their recognized quality. All recommendations are compiled by a multidisciplinary group of experts, based on the available scientific evidence and the collective opinion of the authors.
On April 14, 2021, ESMO published an updated version of the guidelines on small cell lung cancer (SCLC), one of the most aggressive forms of lung cancer, whose prognosis has barely improved for decades because of little progress in available therapies. However, more recently we have seen a renewed interest in research at SCLC, which is finally bearing fruit in terms of new therapeutic options. This justifies the need to update the recommendations in addressing this disease.
This publication covers clinical and pathological diagnosis, staging and risk assessment, treatment and follow-up. Highlight for the treatment algorithms for locoregional, advanced and recurrent disease. Urgent topics such as the place of immunotherapy in the treatment of SCLC, and the indication for prophylactic brain irradiation are also discussed in this article.
An article not to be missed!